Motif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, Iclaprim, and MTF-001, a preclinical program.-based on iclaprim and other lead compounds, the Company is engaged in the development of a lead series with the objective of identifying a DHFRi that is effective against a broad spectrum of gram positive bacteria, including those resistant to available antibiotics, that can be administered once daily in injectable (I/V) and oral (pill) formulations. The Company's other programs include programs in various-stages of development by building a portfolio of antibiotics by licensing drug candidates from organizations specialized in antibacterial research.
London, GB
Size (employees)
4 (est)+300%
Motif Bio is headquartered in London, GB
Report incorrect company information

Motif Bio Office Locations

Motif Bio has an office in London and New York
London, GB (HQ)
1 Tudor St
New York, US
2622 125 Park Ave
Show all (2)
Report incorrect company information

Motif Bio Financials and Metrics

Motif Bio Financials


Net income (FY, 2016)

(30.6 m)

EBITDA (FY, 2016)

(30.1 m)

EBIT (FY, 2016)

(30.1 m)

Market capitalization (2-Oct-2017)

107.1 m

Closing share price (2-Oct-2017)


Cash (2-Mar-2018)

16.6 m
Motif Bio's current market capitalization is £107.1 m.
GBPFY, 2014FY, 2015FY, 2016


2.2 k21.7 m16.6 m

Accounts Receivable

8.2 k

Current Assets

154.6 k21.8 m16.9 m


4.2 m
GBPFY, 2014FY, 2015FY, 2016

Net Income

(811.4 k)(6.5 m)(30.6 m)

Cash From Operating Activities

(1.1 k)(6.1 m)(21.2 m)

Cash From Financing Activities

3.4 k27.8 m16.3 m

Net Change in Cash

2.2 k21.7 m(4.9 m)
GBPY, 2016

Financial Leverage

2.9 x
Show all financial metrics
Report incorrect company information